Have a website account?
for exclusive website content.
to TLCR Journal
Submit Multimedia Files
Peer Review Process
Conflict of Interest
Human and Animal Rights
Publish Ahead of Print
Vol 3, No 6 (December 2014)
Vol 3, No 6 (December 2014): Translational Lung Cancer Research (Personalized Therapy in Lung Cancer)
Special issue on personalized therapy in lung cancer
Na Zhang, Wen-Zhao Zhong, Yi-Long Wu
Highlights in the 14
Central European Lung Cancer Conference (CELCC)
Update on third-generation EGFR tyrosine kinase inhibitors
Jhanelle Gray, Eric Haura
Is the third generation EGFR TKIs the solution for making EGFR mutant NSCLC a curable disease?
Fred R. Hirsch
EGFR, EGFR TKI, and EMSI: a never-ending story
Recent advances in the development of mutant-selective EGFR inhibitors for non-small cell lung cancer patients with EGFR-TKI resistance
Yung-Hung Luo, Yuh-Min Chen
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor—resistant non-small cell lung cancer
Tao Jiang, Caicun Zhou
Clinical development and approval of second generation ALK inhibitors for
rearranged lung cancer
Daniel B. Costa
Ceritinib as a promising therapy for ALK related diseases
Ceritinib—a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer
Sacha I. Rothschild
Gemcitabine-cisplatin plus necitumumab
Necitumumab: a new therapeutic option for squamous cell lung cancer?
Rathi N. Pillai, Suresh S. Ramalingam
Onartuzumab plus erlotinib
A critical question for cancer therapy: what new targets exist?
Rafael Rosell, Niki Karachaliou, Jordi Codony, Cristina Teixido, Silvia Garcia-Roman, Daniela Morales, María González Cao, Santiago Viteri, Ignacio Veliz, Yong Loo, Omar Castillo
Targeting MET in NSCLC: looking for a needle in a haystack
Lorenza Landi, Federico Cappuzzo
Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC
Targeting MET and EGFR in NSCLC—what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?
Michail Charakidis, Michael Boyer
Docetaxel (DOC) and ramucirumab
Angiogenesis and lung cancer: ramucirumab prolongs survival in 2
-line metastatic NSCLC
Millie Das, Heather Wakelee
Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer
Arun Rajan, James L. Gulley
A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors
Christoph C. Zielinski
A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer—the anti-PDL1 antibody—MEDI4736
Sylvia M. Lee, Laura Q. Chow
Reflections on immune checkpoint inhibition in non-small cell lung cancer
Konstantinos Leventakos, Aaron S. Mansfield